PORTOLA VALLEY, Calif., Sept. 2, 2011 /PRNewswire/ -- Spectros Corporation announced today an expansion of its distribution channels in Europe and Asia with the signing of 3 new distributors based in Korea, Switzerland, and Denmark. These groups join other distributors already selling Spectros products outside of the U.S.
"We are excited that distributors are increasingly recognizing the opportunity offered by the superior performance of the T-Stat® 303 VLS Tissue Oximeter," noted Director of Sales Elizabeth van Thillo-Rohlff. "This move accelerates our aggressive expansion into new and emerging markets in Europe and Asia."
Spectros T-Stat and Continuum Oximeters are currently the only solid-state broadband tissue oximeters on the market in the U.S. and Europe. T-Stat and Continuum compete in the ICU and operating rooms with INVOS® oximeters, marketed by Covidien, and FORE-SIGHT® oximeters, marketed by CAS Medical. In reconstructive surgery, T-Stat competes with T.Ox oximeters, marketed by ViOptix, and O2C, marketed in Europe. An expanded array of probes, including broadband NIRS Continuum® cerebral probes are currently in testing, pending FDA approval and release anticipated over the next year.
Spectros markets and licenses advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's champion product, the T-Stat Tissue Oximeter, is the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue. T-Stat is the only commercially-available tissue oximeter that utilizes state-of-the-art solid state broadband visible light (VLS) and broadband near-infrared (NIRS) spectroscopy. The non-invasive T-Stat system is used clinically to provide a continuous and real-time absolute value, utilizing 260 wavelengths to provide superior performance as compared to competing oximeter product lines that only use 2-4.
Copyright©2010 PR Newswire.
All rights reserved